Bayer takeover of Monsanto delayed as US, European regulators seek more information on deal

Screen Shot at PM

The German drugmaker will only seek approval for the transaction in the European Union next quarter after regulators there requested more information, Chief Executive Officer Werner Baumann said at a meeting in Leverkusen, Germany, on Wednesday. The target timing was previously the first quarter. The company is also responding to a second request from the U.S. Department of Justice, he said.

The German company aims to pull off the biggest, most transformative deal of its 152-year history in 2017 as it attempts to meld its own pesticides with Monsanto’s seeds and herbicides.

Unlike Bayer’s, Monsanto’s agriculture business reported positive earnings last month, pointing to a possible turnaround in the industry. Last year, falling crop prices and a quest for greater efficiency triggered a cascade of deals in the industry. DuPont Co. and Dow Chemical Co. await regulatory approval for their planned union, as do China National Chemical Corp. and Switzerland’s Syngenta AG.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Bayer Hints at Delay on Monsanto as Regulators Seek Details

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-Jun-25-2026-12_23_17-PM
No, Bill Gates did not secretly engineer ticks to promote veganism
ChatGPT-Image-Jun-23-2026-03_12_23-PM
Is cellular reprogramming junk science? Nearly 20 patients are getting eye injections in the first FDA-cleared cellular trial
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Screenshot-2026-06-15-at-1.55.27-PM
America's trust in Trump-Kennedy's CDC health recommendations is plunging
ChatGPT-Image-Jun-17-2026-10_52_43-AM
Anguished parents, doctors in tears: Utah’s long measles outbreak takes a toll
ChatGPT-Image-Jun-24-2026-11_36_47-AM
Why the human genome is less a script than a puzzle
ChatGPT-Image-May-18-2026-12_06_18-PM-2
Defying death: The immortality movement goes mainstream

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.